Meeting
2012 ASCO Annual Meeting
A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
Authors
Gayathri Nagaraj
Washington University in St. Louis, St. Louis, MO
Gayathri Nagaraj , Cynthia X. Ma , Jingqin Luo , Matthew J. Ellis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01339442
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS664)
DOI
10.1200/jco.2012.30.15_suppl.tps664
Abstract #
TPS664
Poster Bd #
17C
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.
First Author: Hiroji Iwata
Poster
2020 ASCO Virtual Scientific Program
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
First Author: Robert Wesolowski
Poster
2014 ASCO Annual Meeting
A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).
First Author: Cynthia X. Ma
Poster
2013 ASCO Annual Meeting
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).
First Author: Patrick Y. Wen